

## Press release

### **IBA MEETS FIRST HALF-YEAR REVENUE AND EBITDA TARGETS – REPORTS REDUCED NET DEBT**

Embargo until 5.40 pm (Belgian time) – September 19, 2002

**LOUVAIN-LA-NEUVE, BELGIUM, SEPTEMBER 19, 2002** – IBA (Ion Beam Applications, S.A.:IBOAt.BR) announced today financial results for the six-month period ended June 30, 2002, meeting the company's expectations of 10% - 15% growth in revenue and EBITDA.

Revenue increased 14.6% from €121,223,000 for the six-month period ended June 30, 2001 to €138,942,000 for the six-month period ended June 30, 2002. EBITDA increased 20.4% from €27,612,000 for the six-month period ended June 30, 2001 to €33,235,000 for the six-month period ended June 30, 2002.

In connection with the company's previously announced restructuring program, IBA also reported an extraordinary charge of €7,653,000 for the six-month period ended June 30, 2002 compared with a charge of €34,000 for the same period in 2001. The financial result was a charge of €5,597,000 for the six-month period ended June 30, 2002 compared with a credit of €441,000 for the same period last year when IBA recognized a one-time gain on treasury stock. The increase in the extraordinary result in the first half of 2002 coupled with the one-time gain on treasury stock recognized in 2001 resulted in a reduction in the company's net result from a profit of €3,290,000 in the first half of 2001 to a loss of €8,985,000 in the first half of 2002. IBA's operating result also increased 18.5% from €3,917,000 for the six-month period ended June 30, 2001 to €4,643,000 for the six-month period ended June 30, 2002.

The increase in revenue and EBITDA for the first half is the result of performance in all of the company's three business sectors. Revenues for the six-month period ended June 30, 2002 increased 5.5% in Sterilization and Ionization (S&I), 13.5% in Technology Services and Equipment, and 114.3% in Radioisotopes compared with the same period last year, while EBITDA for the same periods grew by 9.3% in S&I, 101.5% in Technology Services and Equipment, and 67.7% in Radioisotopes.

"We have completed many elements of our restructuring program ahead of schedule," said Pierre Mottet, Chief Executive Officer for IBA. "Our focus on operations, as well as the repayment of certain of the company's debt and the weakened Dollar, has enabled us to reduce IBA's reported net financial debt by 28 million Euros since the close of 2001. We have also experienced good growth in our radioisotopes division and continued sales in proton therapy. We believe that these markets offer significant potential for the future, not only for IBA, but also, and perhaps more importantly, for the advancement of cancer diagnosis and treatment. It is exciting to be involved in the business of saving lives," concluded Mottet.

Looking ahead, IBA expects that total revenue growth for the full year ended December 31, 2002 will be between 5% and 10% compared with the previous year, while EBITDA is expected to be even or moderately increase when compared to 2001.

"The weakening of the Dollar versus the Euro is affecting the reported results of more than 70% of our business," stated James F. Clouser, IBA's President and Chief Operating Officer. "We are also experiencing a slowdown in the rate of growth in the company's sterilization business due to economic conditions in the United States. As a result, we expect sterilization and ionization revenues to increase moderately in Dollar terms during the second half, but anticipate a slight decrease in reported revenues once converted to Euros– the company's reporting currency. We are also anticipating

Chemin du Cyclotron, 3 - 1348 Louvain-la-Neuve, Belgium ☐ Tel.: +32 10 47 58 11 ☐ Fax: +32 10 47 58 10 ☐ Website: <http://www.iba.be>

## Press release

some changes to construction schedules, which may defer some margin recognition on proton therapy systems until next year.”

IBA management also noted that they do not expect a material impact on the company’s current year results relating to a claim of unfair competition and patent infringement filed in August 2002, in United States District Court in California, against IBA by Optivus Technology, Inc., a supplier of proton therapy equipment and services based in San Bernardino, California, USA. The suit seeks certain monetary damages and injunctive relief.

“It is our intent to vigorously protect the company’s interests,” commented Clouser. “We maintain a strong belief in IBA’s proprietary technology position and believe that we have upheld fair business practices.”

“IBA’s performance in the first half of 2002 has been positive in many areas,” continued Clouser. “We have experienced growth in new markets, such as radioisotopes, and we have managed to sustain market share in a troubled US economy. Adding to that our plans for future expansion, our commitment to technology advancements, and our newly restructured and strategically focused organization, we remain confident in IBA’s future.”

### **About IBA**

IBA is a world leader in the fields of medicine and industry, specifically the design and development of particle accelerators, sterilization and ionization services, and the production and distribution of radioisotopes. With more than 50 sites, spanning 12 countries on 3 continents, IBA provide extensive expertise and state-of-the-art services and equipment to numerous world markets in healthcare and industry. A selection of IBA clients include the United States Postal Service, top-ranking medical device manufacturers and specialized centers for the diagnosis and treatment of cancer, such as Massachusetts General Hospital. IBA is listed on the pan-European stock exchange, EURONEXT and is part of the NEXT 150 index and market segment NextEconomy. For further information, visit [www.iba-worldwide.com](http://www.iba-worldwide.com)

### Contacts:

Pleasanton, California US  
Pamela P. Wilkerson, VP, Communications  
Telephone: +925.399.6319  
E-Mail: [pwilkerson@iba-group.com](mailto:pwilkerson@iba-group.com)

Louvain-la-Neuve, Belgium  
Communications Department  
Telephone: +32 10 475 971  
E-Mail: [andre@iba.be](mailto:andre@iba.be)

## Press release

### Key Figures in EUR 000

	Jun 00	Jun 01	Jun 02
Revenue	111,029	121,223	138,942
Operating result (before goodwill amortization)	17,280	10,765	11,236
Operating result as a % of revenue	15.6%	8,9%	8,1%
Operating result	10,655	3,917	4,643
Financial result	(6,247)	441	(5,597)
Current result before taxes & goodwill amortization	11,033	11,206	5,639
Current result before taxes	4,409	4,358	(954)
Extraordinary result	(2,589)	(932)	(7,653)
Goodwill amortization	(6,624)	(6,848)	(6,593)
Result before taxes	1,820	3,426	(8,607)
Net result, share of the Group	421	3,290	(8,985)
No. of shares	24,194,825	24,373,843	24,472,030
Net result per share	0.02	0.13	(0.37)
Shareholders' equity	388,612	407,838	348,684
Net financial debt	102,242	201,045	162,675
Total assets	748,911	787,437	725,261
Headcount	1,165	1,527	1,600

#### REVIEW REPORT ON THE INTERIM CONSOLIDATED FINANCIAL INFORMATION AS OF AND FOR THE HALF YEAR ENDED 30 JUNE 2002 TO THE BOARD OF DIRECTORS OF ION BEAM APPLICATIONS SA

We have reviewed the consolidated interim consolidated financial information of Ion Beam Applications SA as of and for the six-months period ended 30 June 2002, prepared under generally accepted accounting principles in Belgium, and which shows total assets of EUR 725,261 (000) and a loss for the half year - group's share - of EUR 8,985 (000). This consolidated interim financial information is the responsibility of the company's management. Our responsibility is to issue a report on this consolidated financial information based on our review.

We conducted our review in accordance with the recommendation of the "Institut des Reviseurs d'Entreprises" applicable to review engagements. This recommendation requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated interim financial information is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, we are not aware of any material modifications that should be made to the interim consolidated financial information of Ion Beam Applications SA as of and for the six-months period ended 30 June 2002.

Brussels, 17 September 2002

PricewaterhouseCoopers  
 Reviseurs d'Entreprises  
 Represented by  
 Philippe Barbier